🚀 VC round data is live in beta, check it out!
Arbutus Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arbutus Biopharma and similar public comparables like MannKind, UroGen Pharma, MedinCell, ARS Pharmaceuticals and more.
Arbutus Biopharma Overview
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Founded
2005
HQ
Employees
44
Website
Sectors
Financials (LTM)
EV
$809M
Arbutus Biopharma Financials
Arbutus Biopharma reported last 12-month revenue of $11M.
In the same LTM period, Arbutus Biopharma generated had net loss of ($36M).
Revenue (LTM)
Arbutus Biopharma P&L
In the most recent fiscal year, Arbutus Biopharma reported revenue of $6M and EBITDA of ($68M).
Arbutus Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11M | XXX | $6M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($68M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1109%) | XXX | XXX | XXX |
| EBIT Margin | (363%) | XXX | (1134%) | XXX | XXX | XXX |
| Net Profit | ($36M) | XXX | ($70M) | XXX | XXX | XXX |
| Net Margin | (327%) | XXX | (1133%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arbutus Biopharma Stock Performance
Arbutus Biopharma has current market cap of $902M, and enterprise value of $809M.
Market Cap Evolution
Arbutus Biopharma's stock price is $4.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $809M | $902M | 0.0% | XXX | XXX | XXX | $-0.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArbutus Biopharma Valuation Multiples
Arbutus Biopharma trades at 74.3x EV/Revenue multiple, and (11.8x) EV/EBITDA.
EV / Revenue (LTM)
Arbutus Biopharma Financial Valuation Multiples
As of March 21, 2026, Arbutus Biopharma has market cap of $902M and EV of $809M.
Equity research analysts estimate Arbutus Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arbutus Biopharma has a P/E ratio of (25.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $902M | XXX | $902M | XXX | XXX | XXX |
| EV (current) | $809M | XXX | $809M | XXX | XXX | XXX |
| EV/Revenue | 74.3x | XXX | 131.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (11.8x) | XXX | XXX | XXX |
| EV/EBIT | (20.4x) | XXX | (11.6x) | XXX | XXX | XXX |
| P/E | (25.3x) | XXX | (12.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arbutus Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arbutus Biopharma Margins & Growth Rates
Arbutus Biopharma's revenue in the last 12 month declined by (91%).
Arbutus Biopharma's revenue per employee in the last FY averaged $0.2M.
Arbutus Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (91%) | XXX | 121% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1109%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (4%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 358% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 876% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1234% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arbutus Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| UroGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MedinCell | XXX | XXX | XXX | XXX | XXX | XXX |
| ARS Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arbutus Biopharma M&A Activity
Arbutus Biopharma acquired XXX companies to date.
Last acquisition by Arbutus Biopharma was on XXXXXXXX, XXXXX. Arbutus Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arbutus Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArbutus Biopharma Investment Activity
Arbutus Biopharma invested in XXX companies to date.
Arbutus Biopharma made its latest investment on XXXXXXXX, XXXXX. Arbutus Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arbutus Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arbutus Biopharma
| When was Arbutus Biopharma founded? | Arbutus Biopharma was founded in 2005. |
| Where is Arbutus Biopharma headquartered? | Arbutus Biopharma is headquartered in United States. |
| How many employees does Arbutus Biopharma have? | As of today, Arbutus Biopharma has over 44 employees. |
| Who is the CEO of Arbutus Biopharma? | Arbutus Biopharma's CEO is Lindsay Androski. |
| Is Arbutus Biopharma publicly listed? | Yes, Arbutus Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Arbutus Biopharma? | Arbutus Biopharma trades under ABUS ticker. |
| When did Arbutus Biopharma go public? | Arbutus Biopharma went public in 2007. |
| Who are competitors of Arbutus Biopharma? | Arbutus Biopharma main competitors are MannKind, UroGen Pharma, MedinCell, ARS Pharmaceuticals. |
| What is the current market cap of Arbutus Biopharma? | Arbutus Biopharma's current market cap is $902M. |
| What is the current revenue of Arbutus Biopharma? | Arbutus Biopharma's last 12 months revenue is $11M. |
| What is the current revenue growth of Arbutus Biopharma? | Arbutus Biopharma revenue growth (NTM/LTM) is (91%). |
| What is the current EV/Revenue multiple of Arbutus Biopharma? | Current revenue multiple of Arbutus Biopharma is 74.3x. |
| Is Arbutus Biopharma profitable? | No, Arbutus Biopharma is not profitable. |
| What is the current net income of Arbutus Biopharma? | Arbutus Biopharma's last 12 months net income is ($36M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.